FGF-2 in Breast Cancer: Occurrence and Prognostic Significance
Author Information
Author(s): C Yiangou, JJ Gomm, RC Coope, M Law, YA Luqmani, S Shousha, RC Coombes, CL Johnston
Primary Institution: Charing Cross Hospital, London, UK
Hypothesis
Does the expression of fibroblast growth factor 2 (FGF-2) in breast cancer tissues correlate with patient survival outcomes?
Conclusion
Higher levels of FGF-2 expression are associated with improved overall and disease-free survival in breast cancer patients.
Supporting Evidence
- FGF-2 was present in both malignant and non-malignant breast tissues.
- Immunohistochemistry showed lower levels of FGF-2 in malignant tissues compared to non-malignant tissues.
- Kaplan-Meier survival plots indicated that higher FGF-2 levels correlate with better survival outcomes.
Takeaway
This study found that patients with higher levels of a protein called FGF-2 in their breast cancer tissues tend to live longer and have fewer cancer recurrences.
Methodology
The study used semiquantitative RT-PCR, immunohistochemistry, and Western blotting to assess FGF-2 expression in breast cancer tissues.
Limitations
The study is based on a relatively small sample size and requires further validation in larger cohorts.
Participant Demographics
{"age_range":"29-79","mean_age":57,"menopausal_status":{"pre":14,"post":35,"unknown":2},"nodal_status":{"positive":17,"negative":34,"unknown":0},"t_stage":{"T0":1,"T1":13,"T2":25,"T3":6,"T4":3,"unknown":3},"er_status":{"positive":18,"negative":11,"unknown":22}}
Statistical Information
P-Value
{"overall_survival":0.04,"disease_free_survival":0.022}
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website